Viromed Medical AG (ISIN: DE000A40ZVN7), a medical technology company specializing in cold plasma technology, announced the successful completion of a multi-year study on the application of cold atmospheric plasma (CAP) in the lung. The study focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine, and the data will now be submitted for publication in a scientific journal.
The results confirm the potential of cold plasma as a physical, non-pharmacological treatment for severe infectious lung diseases. The data show a clearly defined therapeutic safety window and a complete reduction of pathogenic germs in lung epithelial models. An important component was the ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School, using an isolated, ventilation- and perfusion-capable lung model that reflects key physiological characteristics of the human lung.
Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated: "By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems. It is particularly encouraging that we are already seeing first successful applications in patients in a university clinical setting."
Based on the study results, Viromed's technology has been used in a university setting for a severe pulmonary individual case in a human patient. Following ethics committee approval, a university hospital specializing in lung and transplantation medicine treated a patient with massive complications after a lung transplant. The use of cold plasma was very successful, and the treating physicians described the positive clinical course as exceptional. The hospital plans to publish the case soon, and further severely ill patients with high risk of fatal outcomes are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology, as classical pharmacological therapies are increasingly limited by resistance development. Cold plasma's physical mode of action opens a new therapeutic dimension, also for prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research, such as intracardiac use in operations for bacterial endocarditis or application in the thorax for bacterial pleural empyema.
For more information, visit www.viromed-medical-ag.de.
